Compare DSWL & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSWL | BYSI |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.9M | 58.4M |
| IPO Year | 2000 | 2016 |
| Metric | DSWL | BYSI |
|---|---|---|
| Price | $3.62 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.5K | ★ 30.1K |
| Earning Date | 06-17-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.79 | $0.99 |
| 52 Week High | $4.48 | $2.44 |
| Indicator | DSWL | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 27.27 |
| Support Level | $3.23 | N/A |
| Resistance Level | $3.72 | $1.84 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 59.43 | 15.55 |
Deswell Industries Inc is engaged in the manufacturing and selling of injection-molded plastic parts and components. In addition, it also offers manufacturing services for electronic products and subassemblies and manufactures metallic molds and accessory parts for original equipment manufacturers and contract manufacturers. The company conducts all of its manufacturing activities at separate plastics, electronics and metallic operation factories located in the People's Republic of China. It operates through the Plastic Injection Molding and Electronic Products Assembling segments. The firm offers products such as automobile components, medical testing equipment, parts for audio equipment, av receivers, active subwoofers, digital system key sets, communication products and others.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.